{"organizations": [], "uuid": "cd798e6b0ea8e7fc7674972dccb32ec620832c40", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-nccn-guidelines-recommend-novocure/brief-nccn-guidelines-recommend-novocures-optune-in-combination-with-temozolomide-idUSFWN1R20NH", "country": "US", "domain_rank": 408, "title": "BRIEF-NCCN Guidelines Recommend Novocure's Optune In Combination With Temozolomide", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-20T18:34:00.000+02:00", "replies_count": 0, "uuid": "cd798e6b0ea8e7fc7674972dccb32ec620832c40"}, "author": "", "url": "https://www.reuters.com/article/brief-nccn-guidelines-recommend-novocure/brief-nccn-guidelines-recommend-novocures-optune-in-combination-with-temozolomide-idUSFWN1R20NH", "ord_in_thread": 0, "title": "BRIEF-NCCN Guidelines Recommend Novocure's Optune In Combination With Temozolomide", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "glioblastoma", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "novocure ltd", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 20, 2018 / 4:34 PM / Updated 7 minutes ago BRIEF-NCCN Guidelines Recommend Novocure's Optune In Combination With Temozolomide Reuters Staff 1 Min Read March 20 (Reuters) - Novocure Ltd: * NCCN GUIDELINES RECOMMEND OPTUNE IN COMBINATION WITH TEMOZOLOMIDE AS A CATEGORY 1 TREATMENT FOR NEWLY DIAGNOSED GLIOBLASTOMA * NOVOCURE - ‚ÄçNCCN UPDATED CLINICAL PRACTICE GUIDELINES TO RECOMMEND OPTUNE IN COMBINATION WITH TEMOZOLOMIDE AS CATEGORY 1 TREATMENT FOR NEWLY DIAGNOSED GBM Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-20T18:34:00.000+02:00", "crawled": "2018-03-20T18:47:26.008+02:00", "highlightTitle": ""}